After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
Lexaria has multiple studies planned that will commence early in 2022 DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027 DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time In a strategic move to start off 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that it has signed an advertising and media contract with financial technology company SRAX (NASDAQ: SRAX). The contract will facilitate media buys and digital…